Loading clinical trials...
Loading clinical trials...
Status of Chronic Pain in Patients With Hemophilia.
Hemophilia (A and B) are X-linked hereditary bleeding disorders whose severity depends on the level of coagulation factor (FVIII or FIX respectively). Bleeding is mainly from joints (hemarthrosis) and muscles (hematoma). Nowadays, treatment is based on preventive or curative intravenous infusion of coagulation factor concentrates. Despite these treatments, there is joint deterioration that can be responsible for hemophilic arthropathy and chronic pain. This pain may be related to excess nociception during acute bleeding, but it may also be neuropathic. There are only a few studies that have looked at pain in hemophilia, but it is accepted that the vast majority of patients (especially those with severe forms) suffer from chronic pain. Because patients have become accustomed to this pain and physicians are still not very aware of how to assess it, this pain is not treated effectively. In order to better manage pain in hemophilia, it is therefore necessary to characterize their pain and to know the nociceptive or neuropathic component. The aim of our study is therefore to study the prevalence, the nociceptive or neuropathic profile, the chronic aspect of pain and the main locations of pain in hemophilia. In addition to raising the awareness of physicians in the centers about pain management using specific questionnaires, this survey will help to better define chronic pain in hemophilia of all severities.
This first French assessment of chronic pain in patients with haemophilia will permit to improve and generate new data about chronic pain related to haemophilia, associated-comorbidities, sociodemographic characteristics and analgesic treatments used. These data will be retrieved using several questionnaires in the RedCap web plateform (eCRF). The study will include 6 investigator centres and a minimum of 350 patients during 12 months.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
CHU de Bordeaux
Bordeaux, France
Centre Hospitalier Universitaire de Caen Normandie
Caen, France
CH Métropole Savoie
Chambéry, France
CHU de Clermont-Ferrand
Clermont-Ferrand, France
CHU de Grenoble
Grenoble, France
CHU de LILLE
Lille, France
Hospices Civils de Lyon
Lyon, France
Centre Hospitalier Universitaire de Nantes
Nantes, France
CHU de Saint-Etienne
Saint-Etienne, France
CHU de TOULOUSE
Toulouse, France
Start Date
February 28, 2022
Primary Completion Date
February 28, 2026
Completion Date
August 1, 2026
Last Updated
February 24, 2025
350
ESTIMATED participants
questionnaires
OTHER
Lead Sponsor
University Hospital, Clermont-Ferrand
NCT06379789
NCT07226206
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT05987449